<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='58'><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication/><OriginatorSponsored>N</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules</ProtocolTitle><Trial id="182510"/><TrialEndDateActual>2002-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2002-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2002-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="72458">risperidone (sustained release transdermal jet DosePro/SABER, schizophrenia/bipolar disorder), DURECT</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="1257">Schizoaffective disorder</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><Trial id="226397"/><TrialEndDateActual>2015-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="72458">risperidone (sustained release transdermal jet DosePro/SABER, schizophrenia/bipolar disorder), DURECT</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="299">Schizophrenia</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><Trial id="226397"/><TrialEndDateActual>2015-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients><ProtocolTitle>A Trial Of Two Fixed-Doses of ZX-008 (Fenfluramine Hydrochloride) As An Adjunctive Therapy In Children And Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="265344"/><TrialEndDateActual/><TrialEndDateCalc>2019-06-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients><ProtocolTitle>A Trial Of Two Fixed-Doses of ZX-008 (Fenfluramine Hydrochloride) As An Adjunctive Therapy In Children And Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="265344"/><TrialEndDateActual/><TrialEndDateCalc>2019-06-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47759">sumatriptan (needleless delivery, Intraject), Endo</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="210">Migraine</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients><ProtocolTitle>A Study on the Usability of the Needle-Free Intraject System in Adult Patients During Acute Migraine Attack</ProtocolTitle><Trial id="14101"/><TrialEndDateActual>2007-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-02-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>ZX-008 Expanded Access Protocol</ProtocolTitle><Trial id="364159"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="20">Pain</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients><ProtocolTitle>A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Subjects With Osteoarthritis Pain</ProtocolTitle><Trial id="208687"/><TrialEndDateActual>2002-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2004-01-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2002-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="245">Osteoarthritis</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients><ProtocolTitle>A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Subjects With Osteoarthritis Pain</ProtocolTitle><Trial id="208687"/><TrialEndDateActual>2002-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2004-01-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2002-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>119</Patients><ProtocolTitle>A Trial of Two Fixed Doses of ZX-008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="253849"/><TrialEndDateActual/><TrialEndDateCalc>2018-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>119</Patients><ProtocolTitle>A Trial of Two Fixed Doses of ZX-008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="253849"/><TrialEndDateActual/><TrialEndDateCalc>2018-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3132">Lennox Gastaut syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>225</Patients><ProtocolTitle>A Study to Investigate the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="320689"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-11-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="717">Seizure disorder</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>225</Patients><ProtocolTitle>A Study to Investigate the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="320689"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-11-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3132">Lennox Gastaut syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>225</Patients><ProtocolTitle>A Study to Investigate the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="320689"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-11-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="717">Seizure disorder</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>225</Patients><ProtocolTitle>A Study to Investigate the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="320689"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-11-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="119">Epilepsy</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy</ProtocolTitle><Trial id="250920"/><TrialEndDateActual/><TrialEndDateCalc>2018-04-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2992">Tonic clonic epilepsy</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy</ProtocolTitle><Trial id="250920"/><TrialEndDateActual/><TrialEndDateCalc>2018-04-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3132">Lennox Gastaut syndrome</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy</ProtocolTitle><Trial id="250920"/><TrialEndDateActual/><TrialEndDateCalc>2018-04-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3134">Tonic seizure</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy</ProtocolTitle><Trial id="250920"/><TrialEndDateActual/><TrialEndDateCalc>2018-04-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="20">Pain</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>241</Patients><ProtocolTitle>A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery</ProtocolTitle><Trial id="206204"/><TrialEndDateActual>2003-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2003-11-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2003-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2002-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>87</Patients><ProtocolTitle>A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children &gt;/= 2 Years Old and Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="274612"/><TrialEndDateActual>2019-01-08 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-08-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2019-01-08 00:00:00</TrialEndDateGiven><TrialStartDate>2016-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>87</Patients><ProtocolTitle>A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children &gt;/= 2 Years Old and Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="274612"/><TrialEndDateActual>2019-01-08 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-08-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2019-01-08 00:00:00</TrialEndDateGiven><TrialStartDate>2016-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Efficacy</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="314867"/><TrialEndDateActual/><TrialEndDateCalc>2020-07-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-01-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-01-01 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Efficacy</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="314867"/><TrialEndDateActual/><TrialEndDateCalc>2020-07-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-01-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-01-01 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Efficacy</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients><ProtocolTitle>A phase III, randomized, double-blind, placebo-controlled, European trial of ZX-008 in dravet syndrome children</ProtocolTitle><Trial id="248686"/><TrialEndDateActual/><TrialEndDateCalc>2019-05-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="3132">Lennox Gastaut syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients><ProtocolTitle>A phase I, open-label, randomized, single-dose, 3-period crossover study to evaluate the pharmacokinetics (PK) and safety of fenfluramine with or without a combined antiepileptic drug (AED) regimen of stiripentol (STP), valproate (VPA) and clobazam(CLB; STP regimen) in healthy adults</ProtocolTitle><Trial id="367677"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients><ProtocolTitle>A phase I, open-label, randomized, single-dose, 3-period crossover study to evaluate the pharmacokinetics (PK) and safety of fenfluramine with or without a combined antiepileptic drug (AED) regimen of stiripentol (STP), valproate (VPA) and clobazam(CLB; STP regimen) in healthy adults</ProtocolTitle><Trial id="367677"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47759">sumatriptan (needleless delivery, Intraject), Endo</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><Indication id="210">Migraine</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered via the intraject system</ProtocolTitle><Trial id="18493"/><TrialEndDateActual/><TrialEndDateCalc>2008-05-26 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Efficacy</Endpoint><Indication id="119">Epilepsy</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Treatment of Sunflower Syndrome With ZX-008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4 to 25)</ProtocolTitle><Trial id="365079"/><TrialEndDateActual/><TrialEndDateCalc>2021-05-08 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2019-02-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Efficacy</Endpoint><Indication id="2992">Tonic clonic epilepsy</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Treatment of Sunflower Syndrome With ZX-008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4 to 25)</ProtocolTitle><Trial id="365079"/><TrialEndDateActual/><TrialEndDateCalc>2021-05-08 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2019-02-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47759">sumatriptan (needleless delivery, Intraject), Endo</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="210">Migraine</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>212</Patients><ProtocolTitle>Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine</ProtocolTitle><Trial id="76404"/><TrialEndDateActual>2010-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-04-26 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="72458">risperidone (sustained release transdermal jet DosePro/SABER, schizophrenia/bipolar disorder), DURECT</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="299">Schizophrenia</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia</ProtocolTitle><Trial id="87204"/><TrialEndDateActual>2013-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>A Long-term Prospective study of Fenfluramine in the Patients with Dravet Syndrome</ProtocolTitle><Trial id="162111"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="4236">risperidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="1257">Schizoaffective disorder</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><Trial id="226397"/><TrialEndDateActual>2015-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="4236">risperidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="299">Schizophrenia</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><Trial id="226397"/><TrialEndDateActual>2015-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="26832">risperidone (depot injection, Medisorb), J&amp;J</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="1257">Schizoaffective disorder</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><Trial id="226397"/><TrialEndDateActual>2015-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="26832">risperidone (depot injection, Medisorb), J&amp;J</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="299">Schizophrenia</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><Trial id="226397"/><TrialEndDateActual>2015-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><Indication id="210">Migraine</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered via the intraject system</ProtocolTitle><Trial id="18493"/><TrialEndDateActual/><TrialEndDateCalc>2008-05-26 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="1529">Liver failure</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment</ProtocolTitle><Trial id="211036"/><TrialEndDateActual>2011-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-05-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="20">Pain</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment</ProtocolTitle><Trial id="211036"/><TrialEndDateActual>2011-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-05-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication/><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)</ProtocolTitle><Trial id="184571"/><TrialEndDateActual>2009-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2009-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><Indication id="20">Pain</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients><ProtocolTitle>Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment</ProtocolTitle><Trial id="211235"/><TrialEndDateActual>2011-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-05-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><Indication id="69">Renal failure</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients><ProtocolTitle>Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment</ProtocolTitle><Trial id="211235"/><TrialEndDateActual>2011-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-05-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3132">Lennox Gastaut syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients><ProtocolTitle>A Study to Assess the Safety and Tolerability of ZX-008 in Children and Young Adults With DS or LGS Currently Taking CBD</ProtocolTitle><Trial id="333045"/><TrialEndDateActual/><TrialEndDateCalc>2020-10-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-19 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients><ProtocolTitle>A Study to Assess the Safety and Tolerability of ZX-008 in Children and Young Adults With DS or LGS Currently Taking CBD</ProtocolTitle><Trial id="333045"/><TrialEndDateActual/><TrialEndDateCalc>2020-10-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-19 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3132">Lennox Gastaut syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients><ProtocolTitle>A Study to Assess the Safety and Tolerability of ZX-008 in Children and Young Adults With DS or LGS Currently Taking CBD</ProtocolTitle><Trial id="333045"/><TrialEndDateActual/><TrialEndDateCalc>2020-10-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-19 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients><ProtocolTitle>A Study to Assess the Safety and Tolerability of ZX-008 in Children and Young Adults With DS or LGS Currently Taking CBD</ProtocolTitle><Trial id="333045"/><TrialEndDateActual/><TrialEndDateCalc>2020-10-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-19 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="119">Epilepsy</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="379396"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3132">Lennox Gastaut syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="379396"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="556">Brain disease</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="379396"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="379396"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="119">Epilepsy</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="379396"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3132">Lennox Gastaut syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="379396"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="556">Brain disease</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="379396"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><Trial id="379396"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>232</Patients><ProtocolTitle>An Open-Label, Extension Trial to Assess the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="264975"/><TrialEndDateActual/><TrialEndDateCalc>2019-05-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="5614">Dravet syndrome</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>232</Patients><ProtocolTitle>An Open-Label, Extension Trial to Assess the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome</ProtocolTitle><Trial id="264975"/><TrialEndDateActual/><TrialEndDateCalc>2019-05-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="717">Seizure disorder</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>An open-label, cross-over, phase I pharmacokinetic and safety profile study to determine the effect of food on the pharmacokinetic properties of fenfluramine</ProtocolTitle><Trial id="358598"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row></Rowset>